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Abstract
The association between diabetes and clinical outcomes in patients with advanced nonesmall-cell lung cancer
(NSCLC) is unclear. Therapy with nab-paclitaxel plus carboplatin (nab-P/C) improved the primary end point
(overall response rate) versus solvent-based paclitaxel plus carboplatin (sb-P/C) in the overall population and
in a subset of patients with diabetes in a phase 3 trial of advanced NSCLC. Rate of neuropathy was lower with
nab-P/C versus sb-P/C. nab-P/C is preferable for patients with NSCLC and diabetes.
Purpose: To examine outcomes in a phase 3 trial of nab-paclitaxel plus carboplatin (nab-P/C) versus solvent-based
paclitaxel plus carboplatin (sb-P/C) in a subset of patients with advanced nonesmall-cell lung cancer (NSCLC) and
diabetes. Patients and Methods: Patients with stage IIIB/IV NSCLC received nab-P 100 mg/m2 on days 1, 8, and 15
or sb-P 200 mg/m2 on day 1, both with C at an area under the curve of 6 mg$min/mL on day 1 every 3 weeks. Overall
response rate (ORR) and progression-free survival (PFS) were determined by blinded, independent, centralized review.
P values were based on chi-square test for ORR and log-rank test for overall survival (OS) and PFS. Results: Of the
1052 randomized patients in the phase 3 trial, 61 had diabetes according to prespeciﬁed terms (nab-P/C, 31; sb-P/C,
30). ORR for nab-P/C versus sb-P/C in this subset was 52% versus 27% (relative risk ratio, 1.935; P ¼ .046), median
PFS was 10.9 versus 4.9 months (hazard ratio, 0.420; P ¼ .016), and median OS was 17.5 versus 11.1 months (hazard
ratio, 0.550; P ¼ .057). Treatment differences in PFS remained signiﬁcant (P  .036) after adjusting for histology,
region, stage, race, and age and also remained signiﬁcant in OS for histology (P ¼ .039). Patients with diabetes
experienced lower rates of grade 3 or higher neutropenia and peripheral neuropathy and higher rates of thrombo-
cytopenia and anemia with nab-P/C versus sb-P/C. Conclusion: nab-P/C demonstrated improved efﬁcacy and
manageable tolerability in patients with advanced NSCLC and diabetes.
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Diabetes is a serious and growing health problem.1,2 An esti-
mated 387 million people had diabetes worldwide in 2014, and that
number is expected to rise beyond 592 million in less than 25
years.2 The most recent estimates from 2014 indicate that in North
America, 39 million people were living with diagnosed diabetes and
10.5 million people were living with undiagnosed diabetes.2
Although the exact incidence of diabetes in patients with
advanced nonesmall-lung cancer (NSCLC) has not been wellClinical Lung Cancer September 2016 - 367
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Weekly nab-Paclitaxelstudied, some evidence suggests that patients with diabetes are at an
increased risk of developing certain cancers.3
There are many issues plaguing patients with diabetes and cancer
that can affect treatment outcomes and tolerability.4,5 For example,
diabetes is often accompanied by several complications, including
diabetic neuropathy, which is estimated to develop in up to 50% of
patients.6 Because peripheral neuropathy is also an adverse effect of
many chemotherapeutics, patients with diabetes and cancer could
be prone to this reaction more so than patients with cancer without
diabetes.7 Taxanes, a class of chemotherapeutics associated with
dose-limiting peripheral neuropathy, are commonly used to treat
advanced NSCLC.7-10 Additionally, steroids are particularly prob-
lematic for patients with diabetes because these compounds affect
glucose metabolism and are often implicated as a cause of hyper-
glycemia.11-13 Steroids may also be associated with the development
of diabetes.14 Many solvent-based chemotherapy agents such as
paclitaxel and docetaxel require steroid premedication.10,15
Furthermore, patients with diabetes may also receive suboptimal
therapy due to an increased number of dose reductions or less
aggressive treatment.16,17
While some evidence has suggested that diabetes is associated
with increased survival in lung cancer, several studies have shown
the opposite.18-22 A retrospective study evaluated the prognostic
value of several clinical characteristics of 442 patients with
advanced NSCLC receiving ﬁrst-line, platinum-based doublet
chemotherapy and concluded that the presence of diabetes at
baseline was a signiﬁcant negative prognostic factor for both
progression-free survival (PFS) and overall survival (OS).23 On the
basis of these and other previously published data, improved
treatment options for patients with diabetes and advanced NSCLC
may be needed.18-21,23
nab-paclitaxel in combination with carboplatin (nab-P/C) is
approved for the ﬁrst-line treatment of locally advanced or meta-
static NSCLC in patients who are not candidates for curative sur-
gery or radiation therapy.9 In a large, multicenter phase 3 trial, ﬁrst-
line nab-P/C signiﬁcantly improved the primary end point (overall
response rate [ORR]) over solvent-based paclitaxel plus carboplatin
(sb-P/C; 33% vs. 25%; response rate ratio [RRR], 1.313; 95%
conﬁdence interval [CI], 1.082-1.593; P ¼ .005), with a trend
toward improved OS and PFS.24 nab-P/C was associated with
signiﬁcantly lower rates of grade 3 or higher neuropathy, neu-
tropenia, arthralgia, and myalgia but a higher incidence of throm-
bocytopenia and anemia compared with sb-P/C.
Compared with the solvent-based formulation of paclitaxel, nab-
paclitaxel has demonstrated several distinct pharmacokinetic/phar-
macodynamic advantages, including higher mean maximum serum
concentration of free paclitaxel, higher paclitaxel concentration de-
livery to tumors (preclinical xenograft models), as well as enhanced
transport across endothelial cell monolayers.25,26 In addition, a
recent population pharmacokinetic/pharmacodynamic study
demonstrated that nab-paclitaxel was associated with a faster and
deeper tissue penetration and slower elimination of paclitaxel
compared with the solvent-based formulation in patients with
advanced solid tumors.27 Furthermore, in contrast to solvent-based
paclitaxel, steroid premedication is not required prior to nab-
paclitaxel administration because this formulation does not require
the use of a solvent.9,10Clinical Lung Cancer September 2016The current analysis examined outcomes with nab-P/C versus sb-
P/C in a subset of patients with advanced NSCLC and diabetes
enrolled onto this phase 3 trial.
Patients and Methods
The patients, study design, and methods were previously re-
ported.24 Brieﬂy, chemotherapy-naive patients with histologically or
cytologically conﬁrmed stage IIIB (with or without pleural effusion)
or stage IV NSCLC, measurable by Response Evaluation Criteria in
Solid Tumors (RECIST) v1.0, were eligible for this study. An
Eastern Cooperative Oncology Group performance status of 0 to 1
and a life expectancy of > 12 weeks were required. Patients were
randomly assigned (1:1) to receive either a 30-minute infusion of
nab-P 100 mg/m2 on days 1, 8, and 15 followed by C at an area
under the curve (AUC) of 6 mgmin/mL (per Calvert formula)
provided on day 1 every 21 days or a 3-hour infusion of sb-P 200
mg/m2 plus C AUC 6, both provided on day 1 every 3 weeks.
Stratiﬁcation factors in the phase 3 trial included stage (IIIB vs. IV),
age (< 70 vs.  70 years), sex, region (North America vs. Australia/
New Zealand vs. Eastern Europe vs. Asia/Paciﬁc), and histology
(squamous vs. adenocarcinoma vs. other). At least 6 cycles of
treatment were encouraged, and patients could continue on treat-
ment in the absence of disease progression or unacceptable toxicity
at the investigator’s discretion. Tumors were assessed every 6 weeks
during treatment by spiral computed tomography scans and until
tumor progression after treatment. All patients who received  1
dose of study drug were included in the safety evaluation.
The primary end point of the phase 3 trial was ORR (complete
and partial response) by independent radiologic review according to
RECIST. Secondary end points included PFS by independent re-
view, OS (follow-up for 18 months after treatment), and safety. All
randomized patients were evaluated for efﬁcacy (intent-to-treat
[ITT] population).
Identiﬁcation of Patients With Diabetes
This analysis evaluated the efﬁcacy and safety of nab-P/C and sb-
P/C in patients with and without diabetes enrolled onto this phase 3
trial. Patients with diabetes were identiﬁed based on the pretreat-
ment signs and symptoms reported by investigators. Terms used to
identify patients with diabetes were diabetes mellitus, glucose
tolerance impaired, pancreatogenous diabetes, and type 2 diabetes
mellitus.
Statistical Methods
The percentage of patients with ORR (95% CI) was summarized
for patients with and without diabetes. P values for ORR were based
on the chi-square test, and those for OS and PFS were based on the
log-rank test. Stratiﬁcation (region and histology) was applied in
testing the treatment difference for the nondiabetic population, but
not for the diabetic population due to the small sample size. Adverse
events (AEs) were summarized by the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE) v3.0. PFS and OS treatment comparisons were veriﬁed
by adding a baseline characteristic to the log-rank test as a stratiﬁ-
cation factor. Region (North America/Australia, Eastern Europe, or
Asia/Paciﬁc), histology (squamous or nonsquamous), current stage
of cancer (IIIB or IV), race (white or Asian/African heritage/other),
Table 1 Baseline Characteristics of Patients With and Without Diabetes
Characteristic
Patients With Diabetes Patients Without Diabetes
nab-P/C (n [ 31) sb-P/C (n [ 30) nab-P/C (n [ 490) sb-P/C (n [ 501)
Age, median (range), years 65 (50-81) 65 (49-78) 59 (28-80) 60 (24-84)
Male sex, n (%) 26 (84) 20 (67) 366 (75) 377 (75)
Median weight, kg 75 77 69 70
Median BMI, kg/m2 26.4 26.64 23.99 23.89
Race, n (%)
Asian 10 (32) 8 (27) 69 (14) 72 (14)
African heritage 1 (3) 1 (3) 11 (2) 7 (1)
White 18 (58) 20 (67) 398 (81) 413 (82)
Hispanic/Latino 2 (6) 0 9 (2) 5 (1)
Other 0 1 (3) 3 (1) 4 (1)
ECOG PS, n (%)
0 7 (23) 6 (20) 126 (26) 107 (21)
1 24 (77) 24 (80) 361 (74) 392 (78)
2 0 0 3 (1) 2 (< 1)
Histology, n (%)
Adenocarcinoma 21 (68) 14 (47) 233 (48) 250 (50)
Squamous cell 9 (29) 8 (27) 220 (45) 213 (43)
Carcinoma not otherwise speciﬁed 1 (3) 6 (20) 28 (6) 27 (5)
Large cell 0 2 (7) 9 (2) 11 (2)
Stage at Randomization, n (%)
IIIB 6 (19) 3 (10) 102 (21) 107 (21)
IV 25 (81) 27 (90) 388 (79) 394 (79)
Smoking Status, n (%)
Never smoked 6 (19) 8 (27) 131 (27) 136 (27)
Smoked and quit 21 (68) 19 (63) 147 (30) 129 (26)
Still smokes 4 (13) 3 (10) 210 (43) 231 (47)
Country, n (%)
Australia 0 2 (7) 5 (1) 7 (1)
Canada 1 (3) 3 (10) 20 (4) 20 (4)
Japan 9 (29) 4 (13) 65 (13) 71 (14)
Russia 9 (29) 12 (40) 229 (47) 219 (44)
Ukraine 1 (3) 1 (3) 119 (24) 134 (27)
United States 11 (35) 8 (27) 52 (11) 50 (10)
Metformin therapy, n (%) 10 (32) 11 (37) NA NA
Peripheral Neuropathy, Grade at
Baseline, n (%)
0 22 (73) 25 (86) 475 (97) 477 (95)
1 8 (27) 4 (14) 14 (3) 23 (5)
2 0 0 1 (< 1) 0
Abbreviations: BMI ¼ body mass index; ECOG ¼ Eastern Cooperative Oncology Group; NA ¼ not applicable; nab-p/c ¼ nab-paclitaxel plus carboplatin; PS ¼ performance status; sb-P/C ¼ solvent-
based paclitaxel plus carboplatin.
Vera Hirsh et aland age (< 70 or  70 years) were added to the stratiﬁed log-rank
test one at a time in the sensitivity analysis.
Results
Of the 1052 randomized patients in the study population, 61
were considered to have diabetes according to the prespeciﬁed terms
(nab-P/C, 31; sb-P/C, 30; Table 1) and 991 did not have diabetes
(nab-P/C, 490; sb-P/C, 501). Similar to the ITT population,baseline characteristics were generally well balanced between the
treatment arms in patients without diabetes. Some exceptions in
patients with diabetes were noted. Among patients with diabetes, a
higher percentage of patients treated with nab-P/C were men, had
adenocarcinoma, and were from Japan, while a higher percentage of
patients treated with sb-P/C had carcinoma not otherwise speciﬁed
and were from Russia. In addition, baseline characteristics were
comparable between patients with diabetes versus those withoutClinical Lung Cancer September 2016 - 369
Figure 1 Independent Radiologic Assessment of Overall Response in Patients With and Without Diabetes. aThe 95% CIs for Response
Rate Ratios (RRRs) Were Calculated According to Asymptomatic 95% CI of Relative Risk of nab-Paclitaxel Plus Carboplatin
(nab-P/C) Versus Solvent-Based Paclitaxel Plus Carboplatin (sb-P/C)
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370 -diabetes, regardless of treatment. A higher percentage of patients
with diabetes than those without diabetes previously smoked and
quit, were of Asian origin, were from the United States, and had
adenocarcinoma, while a higher percentage of patients without
diabetes than those with diabetes were white, had squamous his-
tology, currently smoked, and were from the Ukraine. Among pa-
tients with diabetes, 10 (32%) and 11 (37%) in the nab-P/C and
sb-P/C arms received concomitant metformin therapy, respec-
tively. Most patients with or without diabetes had grade 0 peripheral
neuropathy at baseline. However, a higher percentage of patients
with diabetes in the nab-P/C versus sb-P/C arm had grade 1 pe-
ripheral neuropathy at baseline.
Efﬁcacy Results
In patients with diabetes, the ORR was signiﬁcantly higher with
nab-P/C versus sb-P/C (52% vs. 27%; RRR, 1.935; 95% CI,
0.976-3.837; P ¼ .046; Figure 1). nab-P/C treatment also resulted
in a signiﬁcantly longer median PFS compared with sb-P/C in these
patients (10.9 vs. 4.9 months; hazard ratio [HR], 0.42; 95% CI,
0.200-0.868; P ¼ .016; Figure 2A). The median OS was longer in
patients with diabetes receiving nab-P/C versus sb-P/C (17.5 vs.
11.1 months; HR, 0.55; 95% CI, 0.298-1.026; P ¼ .057;Clinical Lung Cancer September 2016Figure 2B), but statistical signiﬁcance was not reached. In patients
without diabetes, nab-P/C treatment also resulted in a signiﬁcant
improvement in ORR versus sb-P/C (31% vs. 25%; RRR, 1.270;
95% CI, 1.039-1.553; P ¼ .019; Figure 1). In addition, the median
PFS with nab-P/C and sb-P/C in these patients was 6.0 and 5.8
months (HR, 0.95; 95% CI, 0.801-1.116; P ¼ .515), respectively,
and the median OS with nab-P/C and sb-P/C was 11.6 and 11.2
months (HR, 0.95; 95% CI, 0.817-1.101; P ¼ .489), respectively.
Sensitivity Analysis
In patients with diabetes, the treatment effect on PFS remained
signiﬁcant for nab-P/C after being adjusted for histology, region,
stage, race, and age (P  .036; Table 2). For OS, the treatment
difference between nab-P/C and sb-P/C in patients with diabetes
was signiﬁcant only when stratifying by histology (P ¼ .039).
Treatment Effects and Exposure
Taxane dose intensity, cumulative dose, and frequency of dose
reductions were higher with nab-P/C versus sb-P/C in patients with
and without diabetes (Table 3). The median number of cycles was
similar in both treatment arms in patients with and without diabetes
(Table 3).
Figure 2 Survival in Patients With Diabetes. (A) Kaplan-Meier Curve of Progression-Free Survival (PFS) in Patients With Diabetes.
(B) Kaplan-Meier Curve of Overall Survival (OS) in Patients With Diabetes
Abbreviations: HR ¼ hazard ratio; nab-P/C ¼ nab-paclitaxel plus carboplatin; pts ¼ patients; sb-P/C ¼ solvent-based paclitaxel plus carboplatin.
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Among patients with diabetes, numerically lower rates of grade 3
or higher neutropenia and higher rates of thrombocytopenia and
anemia were noted with nab-P/C versus sb-P/C (Table 4). With
regard to nonhematologic AEs, a lower incidence of grade 3 or
higher fatigue, arthralgia, and myalgia but a higher incidence of
anorexia was observed with nab-P/C versus sb-P/C treatment.
Incidence of key AEs in patients without diabetes was comparable to
that in patients with diabetes.
In patients with diabetes, grade 3 or higher peripheral neuropathy
was higher with sb-P/C versus nab-P/C. By NCI CTCAE, grade 3
or higher peripheral neuropathy was 7% with nab-P/C versus 20%
with sb-P/C. Similarly, peripheral neuropathy by Medical Dictio-
nary for Regulatory Activities was 7% with nab-P/C versus 20%Table 2 Treatment Effects Adjusted by Stratiﬁcation Factor
for Patients With Diabetes
Efﬁcacy End
Point
Stratiﬁcation
Factor
HR sb-P/C/
nab-P/C Pa
PFS Region 0.32 .010
Histology 0.40 .015
Race 0.45 .036
Stage 0.44 .026
Age 0.39 .013
OS Region 0.54 .055
Histology 0.52 .039
Race 0.56 .066
Stage 0.56 .071
Age 0.57 .069
Abbreviations: nab-P/C ¼ nab-paclitaxel plus carboplatin; OS ¼ overall survival;
PFS ¼ progression-free survival; sb-P/C ¼ solvent-based paclitaxel plus carboplatin.
aBased on stratiﬁed log-rank test.with sb-P/C. In patients without diabetes, sb-P/C treatment also
resulted in higher incidence of grade 3 or higher peripheral neu-
ropathy compared with nab-P/C. Patients with diabetes treated with
nab-P/C generally experienced a longer time to onset of grade 3 or
higher peripheral neuropathy versus those treated with sb-P/C (187
vs. 121 days). In patients without diabetes, time to onset of grade 3
or higher peripheral neuropathy was also longer with nab-P/C versus
sb-P/C (121 vs. 103 days).
Discussion
This analysis described outcomes of a subset of patients with
advanced NSCLC and diabetes enrolled onto a large phase 3 trial.24
The results of this analysis demonstrated that nab-P/C is effective
and well tolerated in patients with advanced NSCLC and diabetes.
In the current analysis of patients with diabetes, nab-P/C resulted in
a signiﬁcantly higher ORR and longer PFS compared with sb-P/C
treatment. Treatment differences in PFS remained signiﬁcant after
adjustment for baseline characteristics, including histology, region,
stage, race, and age. A greater than 6-month improvement in OS
was also observed in the nab-P/C arm, but it did not reach statistical
signiﬁcance. In patients without diabetes, nab-P/C treatment also
resulted in a signiﬁcant improvement in ORR and nonsigniﬁcantly
longer survival outcomes compared with sb-P/C.
No new or unexpected safety signals were noted in patients with
diabetes compared with the ITT population.24 In this analysis, a
numerically lower rate of grade 3 or higher neutropenia and pe-
ripheral neuropathy and a higher rate of thrombocytopenia and
anemia were noted with nab-P/C versus sb-P/C treatment in pa-
tients with and without diabetes. Hematologic events were
manageable with dose modiﬁcations. The incidence of key AEs in
patients with diabetes was comparable with that of patients without
diabetes, further supporting the use of this treatment regimen in this
select patient population.Clinical Lung Cancer September 2016 - 371
Table 3 Treatment Exposure
Parameter
Patients With Diabetes Patients Without Diabetes
nab-P/C (n [ 30) sb-P/C (n [ 30) nab-P/C (n [ 484) sb-P/C (n [ 494)
Median cycles administered, n
(min, max)
6 (1, 24) 5 (1, 25) 6 (1, 31) 6 (1, 30)
Patients who received 6
cycles of therapy, n (%)
17 (57) 15 (50) 249 (51) 266 (54)
Median Dose Intensity
Taxane, mg/m2/wk 79 66 82 65
Carboplatin, AUC/wk 1.50 1.96 1.50 1.95
Median Cumulative Dose
Taxane, mg/m2 1450 900 1313 1150
Carboplatin, AUC 31 27 29 33
Patients With ‡1 Dose
Reduction, n (%)
Taxane 18 (60) 7 (23) 221 (46) 114 (23)
Carboplatin 18 (60) 7 (23) 218 (45) 116 (23)
Abbreviations: AUC ¼ area under the curve; nab-P/C ¼ nab-paclitaxel plus carboplatin; sb-P/C ¼ solvent-based paclitaxel plus carboplatin.
Weekly nab-Paclitaxel
372 -While the correlation remains inconclusive, studies have
demonstrated worse outcomes in patients with cancer and diabetes
compared with patients with cancer but without diabetes.20,22,23 A
prospective, single-center study demonstrated that survival was
signiﬁcantly longer (P ¼ .007) in patients with locally advanced
NSCLC without diabetes (n ¼ 76) versus those with locally
advanced NSCLC and diabetes (n ¼ 11).20 Similarly, in a large
retrospective analysis of 442 patients with advanced NSCLC
receiving ﬁrst-line treatment with platinum doublets, diagnosis of
diabetes at baseline was associated with a signiﬁcantly negative
prognostic inﬂuence on both OS (odds ratio, 2.38; 95% CI,
1.48-3.81; P < .01) and PFS (odds ratio, 1.83; 95% CI, 1.20-2.79;
P ¼ .005).23 In the current study, outcomes appeared to be betterTable 4 Select Grade 3 or Higher Treatment-Related Adverse Event
Adverse Event
Patients With Diabetes
nab-P/C (n [ 30) sb-P/C (n
Hematologic Laboratory
Abnormalities, %
Neutropenia 53 55a
Thrombocytopenia 20 7
Anemia 23 10
Nonhematologic Events, %
Fatigue 7 10
Peripheral neuropathy 7 20
Arthralgia 0 3
Myalgia 0 3
Anorexia 3 0
Abbreviations: CTCAE ¼ Common Terminology Criteria for Adverse Events; nab-P/C ¼ nab-paclita
carboplatin.
an ¼ 29.
bn ¼ 478.
cn ¼ 484.
dn ¼ 483.
Clinical Lung Cancer September 2016in patients with diabetes treated with nab-P/C compared with those
in patients without diabetes, although no formal statistical analyses
were performed between these groups. This trend was not observed
in patients with diabetes treated with sb-P/C.
Patients with diabetes often receive suboptimal treatment, which
can affect outcomes. In this study, the median number of nab-P/C
cycles was 6 in patients with diabetes, which was the same in the ITT
population and patients without diabetes.24 Although a higher per-
centage of patients with diabetes receiving nab-P/C had  1 dose
reduction compared with sb-P/C, dose intensity and cumulative dose
were higher with nab-P/C treatment, and efﬁcacy outcomes did not
appear to be affected. These results indicated that nab-P/C may be a
suitable treatment for patients with diabetes and advanced NSCLC.s by NCI CTCAE
Patients Without Diabetes
[ 30) nab-P/C (n [ 484) sb-P/C (n [ 494)
47b 58c
18b 9d
28b 7c
7 9
3 11
0 2
<1 2
2 1
xel plus carboplatin; NCI ¼ National Cancer Institute; sb-P/C ¼ solvent-based paclitaxel plus
Vera Hirsh et alPatients with diabetes have various complications, making
treatment decisions for patients with cancer and diabetes chal-
lenging.4,5 Chronically high blood glucose levels can injure nerves
and cause a range of neuropathic symptoms.28 Therefore, patients
with diabetes may be particularly susceptible to peripheral neu-
ropathy, which could be exacerbated or aggravated by taxane
treatment. In this trial, nab-P/C treatment was associated with fewer
instances of grade 3 or higher peripheral neuropathy compared with
sb-P/C, and this result was similar in patients with or without
diabetes. A higher percentage of patients with diabetes had grade 1
peripheral neuropathy at baseline in the nab-P/C versus sb-P/C arm.
Despite this, a lower percentage of patients with diabetes treated
with nab-P/C developed grade 3 or higher peripheral neuropathy
compared with those receiving sb-P/C treatment. In addition,
ﬂuctuations in blood glucose are also challenging for patients with
diabetes, and steroids are particularly problematic because they can
increase blood glucose levels and impact glucose metabolism.11
Several chemotherapeutic agents (including solvent-based pacli-
taxel and docetaxel) require steroid premedication to prevent hy-
persensitivity reactions and therefore may be of limited use in this
patient population.10,15,29,30 In contrast, nab-paclitaxel does not
require steroid premedication, which makes it a desirable chemo-
therapeutic option for patients with diabetes.9
It is not known why nab-P/C was particularly effective in patients
with diabetes in the current study. Whether the albumin formula-
tion of nab-paclitaxel plays a role in the differences in outcomes
between patients with diabetes and those without diabetes is un-
known; however, a few studies have provided some high-level evi-
dence of an association. High glucose levels have been shown to
increase cultured endothelial cell permeability to albumin in vitro.31
Similarly, in a rat model of diabetes, hyperglycemia was shown to
alter glomerular albumin permeability.32 Additional studies are
required to clarify this issue. Some evidence has suggested that
metformin may enhance the effects of treatment in patients
with diabetes and various solid tumors, leading to improved
outcomes.33-35 It does not appear that metformin use affected ef-
ﬁcacy outcomes in this study, given that more patients with diabetes
in the sb-P/C versus nab-P/C arm received concomitant metformin
(37% vs. 32%). Further studies are required to investigate the
relationship between use of metformin and outcomes in patients
receiving nab-P/C and whether this relationship is associated with
the mechanism of action of nab-paclitaxel.
While the magnitude of treatment differences between the nab-
P/C and sb-P/C arms was large for each efﬁcacy end point, sample
sizes in this analysis were small, and results should be interpreted in
light of this limitation. The sensitivity analysis should also be
interpreted with caution because it limited the rigor of the stratiﬁed
log-rank test. Finally, it is unknown whether chemotherapy
schedule, pharmacokinetic proﬁle, steroid use, or other factors
contributed to the improved efﬁcacy of nab-P/C versus sb-P/C in
patients with diabetes in this study.
Patients with cancer and diabetes face a signiﬁcant treatment
challenge, given their predisposition to diabetic neuropathy and the
potential exacerbation of this complication by chemotherapeutic
drugs. There is a paucity of data from large-scale trials evaluating the
impact of diabetes on treatment outcomes in patients with NSCLC.
This analysis demonstrated that nab-P/C was effective and welltolerated in patients with advanced NSCLC and diabetes and could
be a valuable treatment option for this subset of patients with a high
unmet need. A prospective, randomized trial of patients with met-
astatic NSCLC and diabetes treated with nab-P/C versus sb-P/C
would be important, especially in view of the increasing incidence
of obesity and diabetes around the world.
Clinical Practice Points
 The global incidence of diabetes continues to rise. Patients with
advanced NSCLC tend to be older; therefore, the risk of dia-
betes may be higher in these patients. The potential predis-
position to chemotherapy-induced peripheral neuropathy makes
treatment particularly challenging in diabetic patients. In a
phase 3 trial of advanced NSCLC, ﬁrst-line nab-P/C treatment
signiﬁcantly improved the primary end point (ORR) versus
sb-P/C. Patients treated with nab-P/C experienced signiﬁcantly
less grade 3 or higher neuropathy, neutropenia, arthralgia, and
myalgia but more thrombocytopenia and anemia compared
with sb-P/C.
 In this retrospective analysis of a subset of patients with diabetes
enrolled onto a phase 3 trial, ORR and PFS were signiﬁcantly
improved with nab-P/C compared with sb-P/C. Similar to results
in the overall population, neutropenia and peripheral neuropathy
were lower with nab-P/C versus sb-P/C in this patient subset.
 nab-P/C appears to be an effective and safe treatment option for
patients with diabetes and advanced NSCLC. Given the need for
therapeutic options in this patient population, additional study
of this treatment combination could be beneﬁcial.Acknowledgments
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